Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupHigh riskICD10C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSequenceChemotherapyChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanNo. Substances12 RadiotherapySupportive therapySupportive substanceCiprofloxacinGranisetronPosaconazoleSupportive substanceCiprofloxacinGranisetronPosaconazoleSupportive substanceCiprofloxacinGranisetronPosaconazoleSupportive substanceCiprofloxacinGranisetronPosaconazoleNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseTherapy intentioncurative or palliativepalliativeRisksAnemia Hb below 8g/dlAstheniaColitisDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperbilirubinemiaInfectionsNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorCortes JECraddock CLübbert MPlatzbecker USchroeder TStratmann JDiseaseAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)OriginCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAProtocols in Revision 6 protocols foundProtocols under revision.Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)
